The benchmark indices opened lower, eventually maintained their gains throughout the session and closed higher.
Indian equity benchmark indices, the Sensex and Nifty 50 indices ended the volatile trade session on a positive note as PSU bank and pharma shares advanced.
At the closing bell, the BSE Sensex closed 107 points higher (up 0.1%)
Meanwhile, the NSE Nifty closed 58 points higher (up 0.2%)
HDFC Bank, Trent, M&M are the top gainers today.
HCL Tech, Tata Steel, Infosys on the other hand, were among the top losers today.
The GIFT Nifty was trading at 25,034 with 53 points higher at the time of writing.
The BSE 150 Midcap index is trading 0.1% higher and the BSE 250 SmallCap index is trading 0.1% lower.
Sectoral indices traded mixed today, with Private Bank sector and power sector witnessed buying. Meanwhile, stocks in telecommunication sector and IT sector witnessed selling pressure.
The rupee is trading at Rs 93.9 against the US$.
Gold prices for the latest contract on MCX are trading 0.6% higher at Rs 1,43,500 per 10 grams.
Meanwhile, silver prices were trading 1.1% higher at 1,87,293 per 1 kg.
IRB Infra Q2 FY27 Results
Shares of IRB Infra came into focus after the company reported its Q2 FY27 results.
IRB Infrastructure Developers Ltd reported a strong financial performance in Q2 FY27, with consolidated net profit rising 84.85% YoY to Rs 2.60 billion, compared with Rs 1.41 billion in the same quarter last year.
The company's total income increased to Rs 189.71 billion from Rs 175.10 billion in the corresponding quarter of the previous financial year.
The growth was supported by a 15% YoY increase in toll revenue, along with distributions received from its Infrastructure Investment Trust (InvIT).
On the operating front, EBITDA grew around 14% YoY to Rs 10.50 billion, while EBITDA margin expanded by 280 basis points to 55.6%, compared with the year-ago period.
Sai Life Sciences Q2 FY27 Results
Shares of Sai Life Science came into focus after the company reported its Q2 FY27 results.
Sai Life Sciences Ltd reported a healthy financial performance in Q2 FY27, with consolidated net profit increasing 17% YoY to Rs 980 million, compared with Rs 840 million in the same quarter last year.
The company's revenue grew 23% YoY to Rs 6.59 billion from Rs 5.37 billion in Q2 FY26, reflecting strong business growth.
EBITDA also increased 20% YoY to Rs 1.87 billion from Rs 1.56 billion in the year-ago quarter. However, EBITDA margin declined slightly to 28% from 29% in the corresponding period last year.
On the expansion front, the company spent Rs 6.21 billion on capital expenditure during the first half of FY27, including Rs 3.58 billion in Q2. It remains on track to achieve its full-year capex target of Rs 11-13 billion.
Additionally, Sai Life Sciences has started operations under its first end-to-end integrated collaboration, which was secured in the previous quarter. The facility is expected to become fully operational in Q3 FY27.
During the quarter, the company also converted another large pharmaceutical client relationship into a strategic engagement. It is further exploring similar integrated outsourcing partnerships with other companies to expand its business.
Comments
Log in or sign up to join the conversation.